A novel inducible acute hyperglycemia mouse model for assessing 6‑KTP

  • Authors:
    • Jinrui Hu
    • Xia Zhong
    • Xiaoping Yang
    • Hongjian Li
    • Yanhong Ran
  • View Affiliations

  • Published online on: July 8, 2019     https://doi.org/10.3892/br.2019.1228
  • Pages: 110-114
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to establish a mouse model of acute hyperglycemia, which may be utilized to detect the glucose concentration‑dependent hypoglycemic activity of the glucagon‑like peptide‑1 derivative, 6‑KTP. The results demonstrated that the first 30 min following the intraperitoneal injection of 2 g/kg glucose into C57BL/6J mice was the optimum time for assessing the hypoglycemic activity of potential therapeutic methods for diabetes. There was a linear association between the dose of 6‑KTP and hypoglycemic activity between 0.2 and 1.2 mg/kg. The resulting model may serve as template for developing cost‑effective in vivo models to test similar therapeutics.

References

1 

Piya MK, Tahrani AA and Barnett AH: Emerging treatment options for type 2 diabetes. Br J Clin Pharmacol. 70:631–644. 2010.PubMed/NCBI View Article : Google Scholar

2 

Drucker DJ and Nauck MA: The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705. 2006.PubMed/NCBI View Article : Google Scholar

3 

Bo A: GLP-1 for type 2 diabetes. Exp Cell Res. 317:1239–1245. 2011.PubMed/NCBI View Article : Google Scholar

4 

Malik DK, Baboota S, Ahuja A, Hasan S and Ali J: Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv. 4:141–151. 2007.PubMed/NCBI View Article : Google Scholar

5 

Pawar R, Ben-Ari A and Domb AJ: Protein and peptide parenteral controlled delivery. Expert Opin Biol Ther. 4:1203–1212. 2004.PubMed/NCBI View Article : Google Scholar

6 

Perry CM: Liraglutide. Drugs. 71:2347–2373. 2011.PubMed/NCBI View Article : Google Scholar

7 

Dunning BE, Foley JE and Ahrén B: Alpha cell function in health and disease: Influence of glucagon-like peptide-1. Diabetologia. 48:1700–1713. 2005.PubMed/NCBI View Article : Google Scholar

8 

Wang Q and Brubaker PL: Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 45:1263–1273. 2002.PubMed/NCBI View Article : Google Scholar

9 

Ding X, Saxena NK, Lin S, Gupta NA and Anania FA: Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. Hepatology. 43:173–181. 2006.PubMed/NCBI View Article : Google Scholar

10 

Del Prato S and Tiengo A: The importance of first-phase insulin secretion: Implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev. 17:164–174. 2001.PubMed/NCBI View Article : Google Scholar

11 

Li HJ, Ma Y, Chen Y, Sang Y, Zhou T, Qiu M, Huang X, Zhou C and Su Z: A protease-based strategy for the controlled release of therapeutic peptides. Angew Chem Int Ed Engl. 49:4930–4933. 2010.PubMed/NCBI View Article : Google Scholar

12 

Berglund O: Different dynamics of insulin secretion in the perfused pancreas of mouse and rat. Acta Endocrinol (Copenh). 93(54)1980.PubMed/NCBI

13 

Voss EM, Bina DM, Mcneil LAD, Johnson ML and Cembrowski GS: Determining acceptability of blood glucose meters: Evaluating a blood glucose testing system. Lab Med. 27:679–682. 1996. View Article : Google Scholar

14 

Collins S, Martin TL, Surwit RS and Robidoux J: Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: Physiological and molecular characteristics. Physiol Behav. 81:243–248. 2004.PubMed/NCBI View Article : Google Scholar

15 

Pan Z: Study of the Biological Characteristics of Sibp: KM mouse. Acta Laboratorium Animalisentia Sinica. 1995.

16 

Pharmacopoeia of the People's Republic of China: Chemical Industry Press, 2015.

17 

Lenzen S: The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 51:216–226. 2008.PubMed/NCBI View Article : Google Scholar

18 

Ramanadham S, Doroudian A and McNeill JH: Myocardial and metabolic abnormalities in streptozotocin-diabetic Wistar and Wistar-Kyoto rats. Can J Cardiol. 6:75–82. 1990.PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hu, J., Zhong, X., Yang, X., Li, H., & Ran, Y. (2019). A novel inducible acute hyperglycemia mouse model for assessing 6‑KTP. Biomedical Reports, 11, 110-114. https://doi.org/10.3892/br.2019.1228
MLA
Hu, J., Zhong, X., Yang, X., Li, H., Ran, Y."A novel inducible acute hyperglycemia mouse model for assessing 6‑KTP". Biomedical Reports 11.3 (2019): 110-114.
Chicago
Hu, J., Zhong, X., Yang, X., Li, H., Ran, Y."A novel inducible acute hyperglycemia mouse model for assessing 6‑KTP". Biomedical Reports 11, no. 3 (2019): 110-114. https://doi.org/10.3892/br.2019.1228